ICH M9 on biopharmaceutics classification system based biowaivers (updated)

22 février 2019


This new multidisciplinary guideline is proposed to address biopharmaceutics classification system (BCS)-based biowaivers. BCS-based biowaivers may be applicable to BCS Class I and III drugs, however BCS-based biowaivers for these two classes are not recognized worldwide. This means that pharmaceutical companies have to follow different approaches in the different regions. This guideline will provide recommendations to support the biopharmaceutics classification of medicinal products and will provide recommendations to support the waiver of bioequivalence studies. This will result in the harmonisation of current regional guidelines/guidance and support streamlined global drug development.


Vous avez aimé cet article ? Partagez le sur les réseaux sociaux :

Découvrez notre dernier livre blanc

En savoir plus